141 related articles for article (PubMed ID: 36734438)
1. Comprehensive immunohistochemical analysis based on the origin of leiomyosarcoma.
Bayçelebi D; Kefeli M; Yıldız L; Karagöz F
Pol J Pathol; 2022; 73(3):233-243. PubMed ID: 36734438
[TBL] [Abstract][Full Text] [Related]
2. Potential diagnostic biomarkers: differential expression of LMP2/β1i and cyclin B1 in human uterine leiomyosarcoma.
Hayashi T; Horiuchi A; Sano K; Hiraoka N; Ichimura T; Sudo T; Ishiko O; Yaegashi N; Aburatani H; Konishi I
Tumori; 2014; 100(4):99e-106e. PubMed ID: 25296613
[TBL] [Abstract][Full Text] [Related]
3. [The differential diagnosis between uterine leiomyosarcoma and the special subtypes of leiomyoma].
Zhu XQ; Shi YF; Cheng XD; Wu YZ
Zhonghua Yi Xue Za Zhi; 2003 Aug; 83(16):1419-21. PubMed ID: 14521746
[TBL] [Abstract][Full Text] [Related]
4. Molecular and immunohistochemical evidence for the origin of uterine leiomyosarcomas from associated leiomyoma and symplastic leiomyoma-like areas.
Mittal KR; Chen F; Wei JJ; Rijhvani K; Kurvathi R; Streck D; Dermody J; Toruner GA
Mod Pathol; 2009 Oct; 22(10):1303-11. PubMed ID: 19633649
[TBL] [Abstract][Full Text] [Related]
5. Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma.
Leitao MM; Soslow RA; Nonaka D; Olshen AB; Aghajanian C; Sabbatini P; Dupont J; Hensley M; Sonoda Y; Barakat RR; Anderson S
Cancer; 2004 Sep; 101(6):1455-62. PubMed ID: 15316901
[TBL] [Abstract][Full Text] [Related]
6. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
[TBL] [Abstract][Full Text] [Related]
7. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis.
Bodner-Adler B; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
Gynecol Oncol; 2005 Jan; 96(1):62-6. PubMed ID: 15589581
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors.
Chen L; Yang B
Int J Gynecol Pathol; 2008 Jul; 27(3):326-32. PubMed ID: 18580309
[TBL] [Abstract][Full Text] [Related]
9. Estrogen and progesterone receptor expression in uterine and extrauterine leiomyosarcomas: an immunohistochemical study.
Kelley TW; Borden EC; Goldblum JR
Appl Immunohistochem Mol Morphol; 2004 Dec; 12(4):338-41. PubMed ID: 15536333
[TBL] [Abstract][Full Text] [Related]
10. The selected biomarker analysis in 5 types of uterine smooth muscle tumors.
Zhang Q; Kanis MJ; Ubago J; Liu D; Scholtens DM; Strohl AE; Lurain JR; Shahabi S; Kong B; Wei JJ
Hum Pathol; 2018 Jun; 76():17-27. PubMed ID: 29258902
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of progesterone receptor and p53 expression in uterine smooth muscle tumors.
Hewedi IH; Radwan NA; Shash LS
Diagn Pathol; 2012 Jan; 7():1. PubMed ID: 22217299
[TBL] [Abstract][Full Text] [Related]
12. Combination of MCM2 With Ki67 and p16 Immunohistochemistry Can Distinguish Uterine Leiomyosarcomas.
Keyhanian K; Lage JM; Chernetsova E; Sekhon H; Eslami Z; Islam S
Int J Gynecol Pathol; 2020 Jul; 39(4):354-361. PubMed ID: 32515921
[TBL] [Abstract][Full Text] [Related]
13. Differential Immunoreactivity of p16 in leiomyosarcomas and leiomyoma variants.
Gannon BR; Manduch M; Childs TJ
Int J Gynecol Pathol; 2008 Jan; 27(1):68-73. PubMed ID: 18156978
[TBL] [Abstract][Full Text] [Related]
14. Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomas.
Schaefer IM; Lundberg MZ; Demicco EG; Przybyl J; Matusiak M; Chibon F; Ingram DR; Hornick JL; Wang WL; Bauer S; Baker LH; Lazar AJ; van de Rijn M; Mariño-Enríquez A; Fletcher JA
Cancer; 2021 Aug; 127(15):2666-2673. PubMed ID: 33788262
[TBL] [Abstract][Full Text] [Related]
15. Atypical Uterine Smooth Muscle Tumors: A Retrospective Evaluation of Clinical and Pathologic Features.
Maltese G; Fontanella C; Lepori S; Scaffa C; Fucà G; Bogani G; Provenzano S; Carcangiu ML; Raspagliesi F; Lorusso D
Oncology; 2018; 94(1):1-6. PubMed ID: 28869928
[TBL] [Abstract][Full Text] [Related]
16. Expression of Ki-67, P53 and progesterone receptors in uterine smooth muscle tumors. Diagnostic value.
Petrović D; Babić D; Forko JI; Martinac I
Coll Antropol; 2010 Mar; 34(1):93-7. PubMed ID: 20437637
[TBL] [Abstract][Full Text] [Related]
17. [Immunohistochemical study of endometrial stromal sarcoma and smooth-muscle tumors of the uterus].
Farah-Klibi F; Ben Hamouda S; Ben Romdhane S; Sfar R; Koubaa A; Ben Jilani S; Zermani R
J Gynecol Obstet Biol Reprod (Paris); 2008 Sep; 37(5):457-62. PubMed ID: 18565690
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of progesterone receptor, p16, p53 and pHH3 expression in uterine atypical leiomyoma.
Liang Y; Zhang X; Chen X; Lü W
Int J Clin Exp Pathol; 2015; 8(6):7196-202. PubMed ID: 26261614
[TBL] [Abstract][Full Text] [Related]
19. Leiomyoma and Leiomyosarcoma (Primary and Metastatic) of the Oral and Maxillofacial Region: A Clinicopathological and Immunohistochemical Study of 27 Cases.
de Araújo GR; Costa SFDS; Mesquita RA; Gomez RS; Dos Santos JN; Pontes HAR; de Andrade BAB; Romañach MJ; Agostini M; Vargas PA; de Cáceres CVBL; Santos-Silva AR; Ribeiro ACP; Brandão TB; Tomasi RA; Ferreyra RS; de Almeida OP; Fonseca FP
Head Neck Pathol; 2022 Mar; 16(1):294-303. PubMed ID: 34106410
[TBL] [Abstract][Full Text] [Related]
20. Cluster analysis of immunohistochemical markers in leiomyosarcoma delineates specific anatomic and gender subgroups.
Carvalho JC; Thomas DG; Lucas DR
Cancer; 2009 Sep; 115(18):4186-95. PubMed ID: 19626649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
